PROCEPT BIOROBOTICS CORP (PRCT) Forecast, Price Target & Analyst Ratings
NASDAQ:PRCT • US74276L1052
27.13 USD
+1.01 (+3.87%)
At close: Mar 13, 2026
27.13 USD
0 (0%)
After Hours: 3/13/2026, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PROCEPT BIOROBOTICS CORP (PRCT).
Forecast Snapshot
Consensus Price Target
$53.81
+ 98.32% Upside
Next Earnings Forecast
Release DateApr 22, 2026
PeriodQ1 / 2026
EPS Estimate-$0.50
Revenue Estimate83.142M
ChartMill Buy Consensus
79.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$53.81
Upside
+ 98.32%
From current price of $27.13 to mean target of $53.81, Based on 20 analyst forecasts
Low
$38.38
Median
$52.02
High
$78.75
Price Target Revisions
1 Month
0.00%
3 Months
-1.82%
Price Target Summary
20 Wall Street analysts provided a forecast for the next 12 months for PRCT. The average price target is 53.81 USD. This implies a price increase of 98.32% is expected in the next year compared to the current price of 27.13.
The average price target has been revised downward by 1.82% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
79.00%
PRCT was analyzed by 20 analysts. The buy percentage consensus is at 79. So analysts seem to be have mildly positive about PRCT.
In the previous month the buy percentage consensus was at a similar level.
PRCT was analyzed by 20 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-06 | Baird | Initiate | Neutral |
| 2026-03-02 | Truist Securities | Maintains | Buy -> Buy |
| 2026-02-26 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-02-26 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-26 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2026-02-26 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-26 | B of A Securities | Downgrade | Neutral -> Underperform |
| 2026-02-26 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-12-18 | Truist Securities | Maintains | Buy -> Buy |
| 2025-12-12 | UBS | Initiate | Buy |
| 2025-12-08 | B of A Securities | Downgrade | Buy -> Neutral |
| 2025-12-02 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-05 | TD Cowen | Maintains | Buy -> Buy |
| 2025-11-05 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-11-05 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-10-15 | Truist Securities | Maintains | Buy -> Buy |
| 2025-09-16 | BTIG | Reiterate | Neutral -> Neutral |
| 2025-09-02 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-08-07 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-07 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-07-15 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-07 | Oppenheimer | Initiate | Perform |
| 2025-04-25 | B of A Securities | Maintains | Buy -> Buy |
| 2025-04-11 | Truist Securities | Maintains | Buy -> Buy |
| 2025-02-26 | Truist Securities | Reiterate | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 22, 2026
PeriodQ1 / 2026
EPS Estimate-$0.50
Revenue Estimate83.142M
Revenue Q2Q20.21%
EPS Q2Q-11.71%
Number of Analysts16
Next Earnings Revisions
Revenue (1 Month)
-12.02%
Revenue (3 Months)
-11.94%
EPS (1 Month)
-52.43%
EPS (3 Months)
-48.94%
Next Earnings Summary
PRCT is expected to report earnings on 4/22/2026. The consensus EPS estimate for the next earnings is -0.5 USD and the consensus revenue estimate is 83.14M USD.
The next earnings revenue estimate has been revised downward by 11.94% in the past 3 months. Downward revisions are a negative sign and indicate that analysts are more pessimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 136.191M 81.56% | 224.498M 64.84% | 308.054M 37.22% | 409.25M 32.85% | 510.18M 24.66% | 595.47M 16.72% | 693.5M 16.46% | 808.35M 16.56% | |
| EBITDA YoY % growth | -105.363M -35.29% | -91.38M 13.27% | -97.469M -6.66% | -20.208M 79.27% | 23.181M 214.71% | 108.19M 366.72% | N/A | N/A | |
| EBIT YoY % growth | -109.17M -35.25% | -96.614M 11.50% | -103.859M -7.50% | -70.258M 32.35% | -42.224M 39.90% | -19.058M 54.86% | -40.881M -114.51% | N/A | |
| Operating Margin | -80.16% | -43.04% | -33.71% | -17.17% | -8.28% | -3.20% | -5.89% | N/A | |
| EPS YoY % growth | -2.24 -18.52% | -1.76 21.43% | -1.71 2.84% | -1.44 15.53% | -0.80 44.52% | -0.37 53.23% | -0.20 46.94% | 0.62 412.82% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.50 -11.71% | -0.37 -7.00% | -0.29 24.62% | -0.21 59.74% | -0.19 61.96% | -0.15 59.82% | -0.15 47.48% | -0.05 77.29% |
| Revenue Q2Q % growth | 83.142M 20.21% | 97.843M 23.57% | 109.26M 31.12% | 121.93M 59.63% | 125.73M 51.22% | 136.23M 39.23% | 136.08M 24.55% | 150.33M 23.29% |
| EBITDA Q2Q % growth | -14.21M 45.27% | -5.583M 70.81% | -1.418M 92.34% | 4.865M 119.74% | 6.518M 145.87% | 7.13M 227.71% | 7.201M 607.84% | 7.813M 60.60% |
| EBIT Q2Q % growth | -30.31M -10.47% | -23.706M -6.84% | -18.305M 21.07% | -12.94M 58.31% | -10.894M 64.06% | -12.199M 48.54% | -12.24M 33.13% | -13.505M -4.36% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
21.21%
EPS Next 5 Year
18.77%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
21.39%
Revenue Next 5 Year
19.41%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
47.43%
EBIT Next 5 Year
N/A
PROCEPT BIOROBOTICS CORP / PRCT Forecast FAQ
What is the price target for PRCT stock?
20 analysts have analysed PRCT and the average price target is 53.81 USD. This implies a price increase of 98.32% is expected in the next year compared to the current price of 27.13.
What is the next earnings date for PRCT stock?
PROCEPT BIOROBOTICS CORP (PRCT) will report earnings on 2026-04-22, after the market close.
What are the consensus estimates for PRCT stock next earnings?
The consensus EPS estimate for the next earnings of PROCEPT BIOROBOTICS CORP (PRCT) is -0.5 USD and the consensus revenue estimate is 83.14M USD.
What is the expected long term growth rate for PROCEPT BIOROBOTICS CORP (PRCT)?
The expected long term growth rate for PROCEPT BIOROBOTICS CORP (PRCT) is 21.39%.